What do the CJEU’s decisions on parallel trade of medicines mean for your company?
At this additional Christmas edition, the IP specialists in our Life Sciences team will discuss the CJEU’s latest decisions on the parallel trade of medicines, and what these decisions mean in practice for your company.
On 17 November 2022, the CJEU delivered essentially two decisions on the parallel trade of medicines. The first concerned the rebranding of generic medicines to the branded reference medicine (in joined cases C-253/20 and C-254/20), and about which we published a blog on 24 November 2022. The second addressed the impact of anti-tampering devices on the possibility, and objective necessity, to rebox (in C-224/20 and C-147/20), and about which we published a blog on 2 December 2022.
Since we have in the meanwhile received further questions about how to deal with these decisions in practice, our specialists Pauline Geentjens and Kirian Claeyé kindly invite you on 21 December 2022 from 14:00 to 15:00 for an additional online webinar. In this webinar, which combines our Life Sciences Sessions with our IP Updates, they will give you their views and advice on implementing these decisions in your day-to-day dealings with the parallel import and parallel distribution of medicines, and they will answer any related questions that you might have.
This webinar will be in English and has been accredited with 1 point by the IBJ/IJE.
Your hosts
